Physicians' Academy for Cardiovascular Education

Management of CV Risk & T2DM: Implications of novel outcome trials

Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona

Video navigation menu

  • Diabetes is a major CV risk factor 00:27
  • The focus in the past was on reducing traditional CV risk factors in diabetes patients. 02:23
  • SGLT2 inhibitors and GLP1 agonists, new types of diabetes drugs, show a CV advantage 05:16
  • Interesting new studies ahead on SGLT2 inhibitors and GLP1 agonists alone or in combination, also in patients who do not have diabetes 11:04

Educational information

The educational objectives of this symposium were to:

Faculty

Prof. John E Deanfield, MD is Professor of Cardiology, Director, National Centre for Cardiovascular Prevention and Outcomes, University College London, United Kingdom

CME Accreditation

This programme was accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Disclosures

This symposum was supported by an unrestricted educational grants provided by Boehringer-Ingelheim/Lilly

Biography, abstract and keyslides View and download slides